About

A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.

PRT2527 is a potent and selective CDK9 inhibitor that demonstrates anti-cancer activity in preclinical models of hematological malignancies and solid tumors with MYC amplification

Yang Zhang, Liang Lu, Min Wang, Dave Rominger, Stefan Ruepp, Kirsten Gallagher, William Gowen-MacDonald, Chaofeng Dai, Miles Cowart, Andrew Combs, Carlo Catapano, Bruce Ruggeri, Peggy Scherle, Kris Vaddi. AACR-NCI-EORTC Annual Meeting 2021; October 7-10, 2021.